TRVN

Trevena, Inc.

0.57 USD

Last updated Dec 6, 00:39 UTC

Yesterday HIGH

$0.6

Yesterday LOW

$0.56

52w HIGH

$3.42

52w LOW

$0.51

EPS

-0.57

PE

-1.00

Next Earnings

Mar 28, 2024

Overview News Government Trades

Trevena, Inc. stock is down -1.36% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November.

Trevena focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

King Of Prussia, United States Of America

Website

trevena.com

Lisa Levin

Wed Aug 16, 2023

Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket

Gainers
Benzinga Newsdesk

Mon Aug 14, 2023

Trevena Q2 EPS $(0.69) Up From $(2.25) YoY, Sales $3.02M

Trevena (NASDAQ:TRVN) reported quarterly losses of $(0.69) per share. This is a 69.33 percent increase over losses of $(2.25) per share from the same period last year. The company reported $3.02 million in sales this
Benzinga Insights

Wed Jul 19, 2023

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Mon Jun 26, 2023

Trevena Announced New Topline Olinvyk Data Highlighting Reduced Cost Per Admission from ARTEMIS Real-World Outcomes Study
Benzinga Newsdesk

Wed May 31, 2023

High-Impact Movers for May 31st

MRKR - 49.5% - Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsJEWL - 45% - Adamas One Acquires Minority Equity Stake in Artificial Intelligence
Benzinga Newsdesk

Wed May 31, 2023

Trevena Receives Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it
richadhand@benzinga.com

Wed May 17, 2023

JMP Securities Reiterates Market Outperform on Trevena, Maintains $2 Price Target

JMP Securities analyst Jason Butler reiterates Trevena (NASDAQ:TRVN) with a Market Outperform and maintains $2 price target.
Benzinga Newsdesk

Mon May 15, 2023

Trevena Expects To Receive Additional $15M Non-dilutive Tranche From R-Bridge Upon First Commercial Sale Of Olinvyk In China
Benzinga Newsdesk

Mon May 15, 2023

Trevena Q1 EPS $(0.81) Beats $(0.98) Estimate, Sales $6.00K Down From $20.00K YoY

Trevena (NASDAQ:TRVN) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 67.34 percent increase over losses of $(2.48) per share from the same
Benzinga Insights

Mon May 15, 2023

Earnings Scheduled For May 15, 2023

Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is projected to report earnings for its first quarter.